Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CAR natural killer cell-based therapies - Shoreline Biosciences

Next Previous
Drug Profile

Research programme: CAR natural killer cell-based therapies - Shoreline Biosciences

Alternative Names: NK cell therapy - Shoreline Biosciences

Latest Information Update: 18 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shoreline Biosciences
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 09 Dec 2023 Preclinical trials in Haematological malignancies in USA (Parenteral) prior to December 2023
  • 09 Dec 2023 Pharmacodynamics data from a preclinical studies in Solid tumour presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 07 Sep 2023 The US District Court for the Southern District of California dismisses patent infringement claims filed against Shoreline Biosciences by Fate Therapeutics and the Whitehead Institute for use of patented iPSCs in Shoreline's drug development programs in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top